Zohar Joseph
Chaim Sheba Medical Center, Department of Psychiatry, Tel Hashomer 52621, Israel.
Expert Rev Neurother. 2008 Mar;8(3):339-49. doi: 10.1586/14737175.8.3.339.
Obsessive-compulsive disorder (OCD) is a chronic, distressing illness that is associated with a specific and unique response to selective serotonin reuptake inhibitors. Escitalopram was granted marketing authorization for the treatment of OCD from the European authorities in 2007 based on results from two Phase-III clinical trials in patients with moderate-to-severe OCD. One, a relapse prevention study, demonstrated substantial efficacy of escitalopram 10-20 mg/day in both acute and maintenance treatment, and the other demonstrated superior efficacy and favorable tolerability of escitalopram compared with placebo during 24-week, double-blind treatment. These data, and other studies reviewed here, suggest that escitalopram is an important additional tool for the treatment of OCD.
强迫症（OCD）是一种慢性、令人痛苦的疾病，与对选择性5-羟色胺再摄取抑制剂的特定且独特反应相关。基于两项针对中重度强迫症患者的III期临床试验结果，艾司西酞普兰于2007年获得欧洲当局的上市许可，用于治疗强迫症。一项预防复发研究表明，艾司西酞普兰10 - 20毫克/天在急性和维持治疗中均具有显著疗效，另一项研究表明，在24周的双盲治疗中，与安慰剂相比，艾司西酞普兰具有更高的疗效和良好的耐受性。此处回顾的这些数据以及其他研究表明，艾司西酞普兰是治疗强迫症的一种重要补充工具。
